Nyxoah Aktie
WKN DE: A2QCWK / ISIN: BE0974358906
26.03.2025 08:18:35
|
Nyxoah: FDA Issues Approvable Letter Regarding Pre-Market Approval Application For Genio System
(RTTNews) - Nyxoah SA (NYXH) announced the FDA has issued an Approvable Letter regarding the Pre-Market Approval application for the Genio system. The Approvable Letter means that Nyxoah's application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDAs PMA implementing regulations, and the FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review.
The company said the decision does not impact Genio's CE Mark or ongoing commercial activities in Europe.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nyxoah S.A. Registered Shsmehr Nachrichten
15.09.25 |
EQS-News: Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. (EQS Group) | |
15.09.25 |
EQS-News: Nyxoah reicht Klage wegen Patentverletzung gegen Inspire Medical Systems, Inc. ein (EQS Group) | |
18.08.25 |
EQS-News: Nyxoah Reports Second Quarter Financial and Operating Results (EQS Group) | |
18.08.25 |
EQS-News: Nyxoah gibt Finanzergebnisse und operatives Update für das zweite Quartal bekannt (EQS Group) | |
17.08.25 |
Ausblick: Nyxoah präsentiert Quartalsergebnisse (finanzen.net) | |
11.08.25 |
EQS-News: Nyxoah Announces Preliminary Results for the Second Quarter of 2025 (EQS Group) | |
11.08.25 |
EQS-News: Nyxoah gibt vorläufige Finanzergebnisse für das zweite Quartal 2025 bekannt (EQS Group) | |
08.08.25 |
EQS-News: Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea (EQS Group) |
Analysen zu Nyxoah S.A. Registered Shsmehr Analysen
Aktien in diesem Artikel
Nyxoah S.A. Registered Shs | 3,72 | -7,13% |
|